{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:03:10Z","timestamp":1782842590822,"version":"3.54.5"},"reference-count":44,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sedation at the end of life is used to relieve distressing symptoms including agitation and delirium. Standard care may include infused benzodiazepines or antipsychotics. These agents often result in deep sedation with loss of interaction with loved ones, which may be distressing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The DREAMS (Dexmedetomidine for the Reduction of End-of-life Agitation and for optiMised Sedation) trial aimed to compare the sedative and antidelirium effects of the alpha-2 agonist dexmedetomidine, a novel palliative care sedative, compared with midazolam, a benzodiazepine when administered by subcutaneous infusion at the end of life, with doses of both agents targeting lighter, or potentially interactive sedation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants were recruited from adult inpatients admitted for end-of-life care under a palliative care team in regional New South Wales, Australia. Inclusion criteria included patients older than 18 years, with a preference for lighter sedation at the end of life. Exclusion criteria included severe cardiac dysfunction (contraindication to dexmedetomidine). Participants consented and were placed on a treatment-pending list. Upon experiencing terminal deterioration, patients were randomized to either arm 1 (dexmedetomidine) or arm 2 (midazolam) as their treatment arm. These treatments were administered by continuous subcutaneous infusion. The level of consciousness and agitation of the patients were measured by the Richmond Agitation-Sedation Scale\u2013Palliative version and the Memorial Delirium Assessment Score. Richmond Agitation-Sedation Scale\u2013Palliative version assessments were performed by both nursing and medical staff, while Memorial Delirium Assessment Score assessments were carried out by medical staff only. Families and patients were asked to complete, as able, a patient comfort assessment form, to gauge perceptions of distress. Data were collected and matched with the breakthrough medication doses administered, along with qualitative comments in the medical record. In addition, the study tracked symptoms and patient functional status that were recorded as part of the Palliative Care Outcomes Collaborative, a national tracking project for monitoring symptom outcomes in palliative care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The DREAMS trial was funded in May 2020, approved by the ethics committee in November 2020, and started recruiting participants in May 2021. Data collection commenced in May 2021 and is anticipated to continue until December 2024. Publication of results is anticipated from 2024 to 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The evidence base for sedative dosing in palliative care for distress and agitation is not robust, with standard care based primarily on clinical experience and not robust scientific evidence. This study is important because it will compare a standard and a novel sedative used in end-of-life treatment. By assessing the potential efficacy and benefits of both, it seeks to optimize the quality of dying by providing targeted sedation that can improve the communication between dying patients and their loved ones.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Australia New Zealand Clinical Trials Register ACTRN12621000052831; https:\/\/uat.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=380889<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>International Registered Report Identifier (IRRID)<\/jats:title>\n                    <jats:p>DERR1-10.2196\/55129<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/55129","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T15:42:00Z","timestamp":1719330120000},"page":"e55129","source":"Crossref","is-referenced-by-count":4,"title":["Dexmedetomidine Versus Midazolam for End-of-Life Sedation and Agitation: Protocol for a Randomized Controlled Trial (The DREAMS Trial)"],"prefix":"10.2196","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0968-2071","authenticated-orcid":false,"given":"Benjamin","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9135-4469","authenticated-orcid":false,"given":"Greg","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-1977","authenticated-orcid":false,"given":"Wing-Shan Angela","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3772-7986","authenticated-orcid":false,"given":"Judy","family":"Mullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1472-4697","authenticated-orcid":false,"given":"Kylie","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1002\/1097-0142(20000615)88:12<2859::AID-CNCR29>3.0.CO;2-T","volume":"88","author":"Lawlor, PG","year":"2000","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004770.pub2"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0804-3"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010206.pub2"},{"key":"ref5","unstructured":"ANZSPMPalliative Sedation Therapy: Guidance Document20172024-07-05https:\/\/www.safercare.vic.gov.au\/sites\/default\/files\/2020-03\/GUIDANCE_Palliative%20sedation%20therapy%20FINAL.pdf"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/0269216309107024"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2009.05.012"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2019.07.033"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1178224218823511"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(88)91057-4"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(90)90020-k"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/026921638900300411"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1991.tb93848.x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/026921639100500310"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1191\/026921600666097479"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.06.019"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0034-7094(12)70110-1"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1049909110389804"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1987.tb11220.x"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/0269216321994440"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/0269216314556923"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/s0885-3924(02)00423-2"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2018.0516"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-19-0125"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S404934"},{"key":"ref26","unstructured":"Orion CorporationDexmedetomidine 0.5 mg\/ml solution for injection: summary of product characteristics20232024-07-05European Medicines Agencyhttps:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dexdomitor-epar-product-information_en.pdf"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-018-0562-0"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000000931"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2461-1"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/1472-684X-13-17"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s0885-3924(96)00316-8"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/s0885-3924(03)00286-0"},{"key":"ref33","unstructured":"Guardianship Act 1987 No 257New South Wales Government19872024-07-05https:\/\/legislation.nsw.gov.au\/view\/whole\/html\/inforce\/current\/act-1987-257"},{"key":"ref34","unstructured":"A practical handbook for health professionals: how to safely set up, commence and provide necessary documentation for NIKI T34TM, T34TM and BodyGuardTM T syringe pump infusionsBrisbane South Palliative Care Collaborative20222024-07-05Brisbane South Palliative Care Collaborativehttps:\/\/www.caresearch.com.au\/portals\/10\/Documents\/NIKI-BodyGuard-pump-handbook-WEB-update-FINAL.pdf"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2015.2872"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108838"},{"key":"ref37","author":"Twycross, R","year":"2018","journal-title":"Palliative Care Formulary"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2016.12.335"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1017\/S1478951514000613"},{"key":"ref40","unstructured":"Palliative Care Outcomes Collaboration, Research and Data20232023-11-01University of Wollongonghttps:\/\/www.uow.edu.au\/ahsri\/pcoc\/research-data\/"},{"key":"ref41","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.020172024-07-14https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1080\/08989621.2011.622173"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1177\/0269216317744503"},{"key":"ref44","unstructured":"The last days of life toolkit20162024-07-05Clinical Excellence Commissionhttps:\/\/www.cec.health.nsw.gov.au\/keep-patients-safe\/end-of-life-care\/last-days-of-life"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2024\/1\/e55129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:42:35Z","timestamp":1782841355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2024\/1\/e55129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":44,"URL":"https:\/\/doi.org\/10.2196\/55129","relation":{"has-preprint":[{"id-type":"doi","id":"10.2196\/preprints.55129","asserted-by":"object"}]},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]}}}